Questioning the need to use botox within 4 hours of reconstitution: A study of fresh vs 2-week-old botox

Archives of Facial Plastic Surgery

Volumn 10, Issue 4, 2008, Pages 273-279

  Yang, George C ^a   Chiu, Robert J ^a   Gillman, Grant S ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG STORAGE; FACE MUSCLE; FEMALE; FOREHEAD; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MIDDLE AGED; MUSCLE CONTRACTION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BOTULINUM TOXIN TYPE A; DOUBLE-BLIND METHOD; DRUG STORAGE; FACIAL MUSCLES; FEMALE; FOREHEAD; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MUSCLE CONTRACTION; NEUROMUSCULAR AGENTS;

EID: 48349120823     PISSN: 15212491     EISSN: 15383660     Source Type: Journal    
DOI: 10.1001/archfaci.10.4.273     Document Type: Article

References (13)

1. Flynn TC, Carruthers JA, Carruthers JA. Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg. 2001;27(8):703-708.
2. Fagien S, Brandt FS. Primary and adjunctive use of botulinum toxin type a (Botox) in facial aesthetic surgery. Clin Plast Surg. 2001;28(1):127-148.
3. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56(1):80-99.
4. Pearce LB, Borodic GE, First ER, MacCallum RD. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol. 1994;128 (1):69-77.
5. Botox [package insert]. Irvine, California: Allergan Inc; 2000.
6. Gartlan MG, Hoffman HT. Crystalline preparation of botulinum toxin type A (Botox): degradation of potency with storage. Otolaryngol Head Neck Surg. 1993;108(2):135-140.
7. Greene P. Potency of frozen/thawed botulinum toxin type A in the treatment of torsional dystonia. Otolaryngol Head Neck Surg. 1993;109(5):968-969.
8. Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg. 1998:24(11):1179-1180.
9. Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology. 1997;48(1):249-253.
10. Garcia A, Fulton JE. Cosmetic denervation of the muscles of facial expression with botulinum toxin: a dose-response study. Dermatol Surg. 1996;22(1):39-43.
11. Hexsel DM, De Almeida AT, Rutowitsch M, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg. 2003;29(5):523-529.
12. Jabor MA, Kaushik R, Shayani P, et al. Efficacy of reconstituted and stored botulinum toxin type A: an electrophysiologic and visual study in the auricular muscle of the rabbit. Plast Reconstr Surg. 2003;111(7):2419- 2426.
13. Thomas JP, Siupsinskiene N. Frozen versus fresh reconstituted Botox for laryngeal dystonia. Otolaryngol Head Neck Surg. 2006;135(2):204-208.